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Drugs of the salicylate family (aspirin-like drugs) are reversibly ototoxic. Electrophysiologic and ultrastructural evidence suggests an 
impairment of the sensory hair cells of the cochlea following salicylate treatment. In addition, since these drugs can cause vasoconstriction, the 
ototoxicity of salicylates may also involve an impairment of the blood circulation in inner ear. However, a vascular hypothesis of salicylate toxicity 
has not received much attention. In the current study, we simultaneously measured cochlear blood flow (by laser Doppler flowmetry) and the 
sound-evoked potentials from the round window. Sodium salicylate caused a decrease in cochlear blood flow that appeared within 30 min 
following an intramuscular injection of a low dose of sodium salicylate (100 mg/kg). This sodium salicylate dose did not cause a change in 
auditory sensitivity. For higher doses (200 mg/kg and 300 mg/kg), both cochlear blood flow and auditory sensitivity were affected. The 300 
mg/kg dose decreased blood flow by about 25% and elevated compound action potential thresholds by 10 to 25 dB for high frequencies ( 2 8 
kHz). Further experiments showed that salicylate-induced threshold shifts were significantly reduced for the mid-frequencies when cochlear 
blood flow is increased by the vasodilating drug hydralazine (negating the flow reduction caused by salicylate). These data indicate that in 
addition to the direct effect of systemically administered salicylate on neurosensory function a decreased blood flow contributes to the ototoxicity 
of salicylates. 
Sodium salicylate; Laser doppler flowmetry; Cochlea; Guinea pig; Hydralazine; Topical drug application 
Introduction 
Aspirin, related salicylate compounds, and other 
anti-inflammatory drugs are often prescribed for pro- 
longed use at medium to high doses in the treatment of 
arthritis and other conditions. These therapeutic doses, 
as well as accidental intoxications with salicylate, have 
been reported to cause reversible hearing impairments. 
Some characteristics of this ototoxicity have been well 
described but its mechanism is still unclear. Salicylates 
cause tinnitus and auditory threshold shifts affecting 
the whole range of frequencies but more strongly at 
the highest frequencies of audition (Myers and Bern- 
stein, 1965; McCabe and Dey, 1965; Bernstein and 
Weiss, 1967; Ramsden et al., 1985). The adverse effects 
of salicylates on hearing are always totally reversible 
within 1 to 2 days following the last drug treatment 
(Myers and Bernstein, 1965; McCabe and Dey, 1965; 
Bernstein and Weiss, 1967; Ramsden et al., 1985). The 
effect of salicylates on the electrophysiology of the 
cochlea has also been studied in different animal mod- 
els (guinea-pig: Puel et al., 1990; Cazals et al., 1988; 
McPherson and Miller, 1974; Mitchell et al., 1973; 
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squirrel monkey: Myers and Bernstein, 1965; Cat: Sil- 
verstein et al., 1967; Evans and Borerwe, 1982; Sty- 
pulkowski, 1990; chinchilla: Deer and Hunter-Duvar, 
1982). All these studies showed salicylate-induced 
cochlear sensitivity shifts similar to those found in 
human hearing, i.e., reduced sensitivity ranging from 5 
to 40 dB, depending on the dose and the species used. 
Salicylates were also found to reduce the amplitude of 
the whole cochlear nerve action potential (CAP) evoked 
by low intensity sounds (for the most recent data, see 
Puel et al., 1990, Stypulkowski, 1990). 
The presence of salicylate-induced tinnitus in ani- 
mals, similar to that found in human, has been strongly 
indicated by indirect observations (Evans and Borerwe, 
1982; Jastreboff et al., 1988). It has also been observed 
that human spontaneous oto-emissions are suppressed 
and evoked oto-emissions are reduced by salicylates 
(McFadden and Plattsmier, 1984; Long and Tubis, 
1988). 
Salicylates reduce the amplitude of the whole 
cochlear nerve action potential evoked by low intensity 
sounds (Silverstein et al., 1967; Mitchell et al., 1973; 
McPherson and Miller, 1974; Cazals et al., 1988; Puel 
et al., 1990; Stypulkowski, 1990). However, the litera- 
ture provides a more controversial picture of the effect 
of salicylates on the cochlear microphonic, which can 
show increase, decrease or no change (Stypulkowski, 
1990; Mitchell et al., 1973; Shehata et al., 1991; Cazals 
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et al., 1988; McPherson and Miller, 1974; Silverstein et 
al., 1967; Puel et al., 1990). It has also been observed 
that human oto-emissions are suppressed by salicylates 
(McFadden and Plattsmier, 1984; Long and Tubis, 
1988). 
Taken together, the data of the above studies 
strongly indicate that the outer hair cell is the target 
for the toxicity of salicylates. For example, in the study 
by Stypulkowski (1990) sali~late-induced changes in 
cochlear function was attributed to an increase in outer 
hair cell membrane conductance, interfering with the 
transduction process. Salicylate-induced increase in 
membrane conductance has been confirmed in isolated 
outer hair cells (Shehata et al., 1991). In contrast to the 
physiological evidence, many anatomical studies have 
failed to show a hair cell pathology following salicylate 
intoxication that could account for the electrophysio- 
logic changes. Ultrastructural observations have gener- 
ally revealed no anatomical alterations of the hair cells, 
even when a significant 1eveI of hearing loss was 
achieved (Myers and Bernstein, 1965; Deer and 
Hunter-Duvar, 1982; Crifo, 1975) but some ultrastruc- 
tural studies show that salicylates may be able to alter 
the structure of the outer hair cell subsurface cisternae 
(Douek et al., 1983; Dieler et al., 1991). 
In addition to a possible action on hair cells, salicy- 
lates have been proposed to cause metabolic distur- 
bances in the cochlea. Anatomical observations on 
surface preparations of the stria vascularis have indi- 
cated a possible reduction in blood flow induced by 
salicylates (Hawkins, 1976; Perez de Moura, 1968). An 
autoradiographic study has demonstrated the presence 
of salicylates in the capillaries of the stria vascularis 
and the spiral ligament. SmalIer amounts of salicylate 
also appeared, with some delay, in the perilymphatic 
and endolymphatic spaces and in the organ of Corti 
(Ishii et al., 1967). The proposal that salicylate targets 
vascular mechanisms derives from its inhibitory action 
on the synthesis of prostaglandins (Vane, 1971; Escou- 
bet et al., 1985) and on its stimulatory effect in the 
production of leukotrienes (Jung et al., 1989; 1992). 
While the specific role of these metabolites in the 
cochlea is still largely unknown, among the 
prostaglandins (PGs), prostacyclin (PGI2) and PGE2 
have been shown to be potent dilating agents in other 
systems (Moncada, 1982). The interaction of salicylate 
with epinephrine, a vasoconstrictive sympatho-mimetic 
(Cazals et al., 1988), also supports a vascular action of 
salicylate. Furthermore, excessive levels of leukotrienes 
could mediate a decreased cochlear blood flow (CBFI 
(Jung et al., 1991). 
The goal of the present study was to test the vascu- 
lar hypothesis of the ototoxicity of salicylates. In the 
guinea-pig, we measured the CBF using a laser Doppler 
~owmeter (LDF) folIowing both systemic and topical 
(on the round window membrane) administration of 
sodium salicylate. We assessed the relationship of CBF 
changes to sensitivity loss in some experiments. The 
first portion of the study focused on the effects of 
sodium salicylate alone. In the second part, we investi- 
gated the dependency of cochlear physiology on CBF 
by measuring the vascular and physiological effects of a 
dilating agent, hydralazine, on the toxicity of sodium 
salicylate. 
Material and Methods 
Animal preparation 
Pigmented guinea-pigs (N = 46), weighing 250-450 
g, of either sex were used. They were anesthetized with 
sodium pentobarbital(7.5 mg/kg ip) followed by Inno- 
var-Vet (0.2 ml/kg, im). Additional half doses were 
given every 2 h (sodium pentobarbital) or every hour 
(Innovar-Vet). The animals were kept at 38°C with a 
thermo-regulated heating pad. A tracheotomy was per- 
formed and the animals breathed freely through the 
tracheal tube. The head was secured in a head-holder 
heated to avoid cooling of the cochlea (Brown et al., 
1983a). The left carotid artery was cannuiated and the 
catheter (PE 50 tubing) connected to a pressure trans- 
ducer so that the systemic blood pressure (BP) was 
monitored throughout the experiment. The right audi- 
tory bulla was exposed by a ventro-lateral approach. 
Care was taken to assure that the bulla opening was 
performed without noise trauma (Brown et al., 1983b). 
Electroph~siologica~ recordings 
A Teflon-coated platinum electrode was placed on 
the round window membrane. Tone burst sound stim- 
uli (1.5 ms duration, 1 ms rise-fall time, lO/sec) were 
produced by a l/2” Briiel & Kjaer microphone using a 
closed field sound speculum fitted into the ear canal. A 
l/2” Briiel & Kjaer probe microphone system moni- 
tored the sound level near the tympanic membrane. 
Thresholds for the compound action potential (CAP) 
were determined visually after averaging 256 tone 
bursts, at 24, 8, 24 and 32 kHz. A threshotd amplitude 
of N, deflection of the CAP was appro~mately 1 pV. 
Isopotential cochlear mi~rophonic (CM) curves (1 PV 
rms) were also taken, in response to continuous pure 
tones. Electrophysiological measurements were done 
before and 30, 60,90 and/or 120 min after the admin- 
istration of sodium salicylate. 
Cochlear blood flow measurements 
The probe of a LDF (TSI Laserflow model 403, 
probe diameter 0.7 mm) was placed over the lateral 
wall of first cochlear turn. The output of the LDF, as 
well as the systemic BP, were recorded on a chart 
recorder. The computed ratio of CBF to BP, which we 
call R, was also recorded. R allows the evaluation of 
the CBF changes not directly related to systemic BP 
changes, Changes in CBF, R, and BP were measured 
from the chart recordings at different time intervals 
following the administration of drugs, These intervals 
were variable (from 2 to 30 min) depending on the 
experiment and arc specified in the resuits. For each 
time-poinr, averages were calculated across animals 
within each group. Data are expressed as percentage 
change from a baseline determined from a 10 to 20 min 
period prior to application of the drug. Electrophysio- 
logical data and CBF data were usually obtained from 
the same animals. For technical reasons, for 3 cases in 
the 200 mg/kg group, only CBF was obtained and for 
one case in the 300 mg/kg group, only electrophysiol- 
ogy was obtained. 
Sodium salicylate, freshly dissolved in saline, was 
bjected i~tr~uscu~ar~y at doses of I00 (N = 31, 200 
0V = 71, or 300 UV = 5) mg/kg. In three additionaI 
groups, 1 pl of sodium salicylate was applied topically 
on the round window membrane* in the manner used 
by OhXs&r et al., (1990) at freshly prepared concentra- 
tions of 100 mM (N = 3), 200 mM (N = 91, or 300 
(N = 4) mM. For both systemic (N = 4) and topica 
(N = 4) experiments, control experiments were per- 
formed in which saline replaced sodium salicyIate. 
The administration of 3W mg/kg of sodium saIicy- 
Iate was combined with the topical application of hy- 
dralazine as follows: A first group fgraup SH) (N = 5) 
received the intramuscular injection of sodium salicy- 
late f&lowed 30 min later by the topical application of 
I JLI af hydralazine solution at the concentration of 20 
mg/mI. A second group (group HS) (N = 5) received 
the application of hydralazine followed 3Q min later by 
the injection of sodium salicylate. In a third group 
(N r= 4), we apphed only hydralazine (group H). A 
group S was constituted of the guinea-pigs that re- 
ceived 300 nag/kg of sodium salicylate in the first part 
of the study. CBF was monitored continuously, and 
evoked potentials were measured before administra- 
tion of any drug and 2 h following the injection of 
sodium salicylate in group S, SH, and HS or 2 h 
following the application of hydralazine in group H. 
The intramuscuIar administration of sodium s&y- 
late caused a dose-dependent decrease in CBF. During 
the first half hour following the injection of the highest 
dose, it fell by 25%. In contrast, I3P increased (10%) 
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Fig. 1. The changes ir~ the ratio of CBF ta BP III) expressed as 
percent af baseline fotlowing systemic im injecthns of saline or 
sodium sakylate at three difkrent dose levels. 
irnmediateIy fohowing the injection, returned to base- 
line by 10 to 15 min post injection, and continued a 
very slaw decline to 80% of the pre-drug value. As a 
result of the combined CBF and BP changes, R de- 
creased but stabilized at 90% of the initial value by 30 
min following the injection of 100 mg/kg (Fig. 1). For 
the higher dases, (200 and 300 mg/kg), the decrease in 
R stabilized at a level of 75% of its initial level. Both 
the 200 mg/kg and 300 mg/kg dose produced the 
same R reduction and R did not show recovery by 120 
min following any of the saIicylate doses (Fig. 1). 
The CAP threshold shifts associated with the admin- 
istration of sodium salicylate are shown in Fig, 2. The 
lowest dose (100 mg/kg) did not produce any signifi- 
cant sensitivity change. FolIowing 200 and 300 mg/kg, 
changes in sensitivity resemble those described in the 
literature. The high frequencies (above 8 kHz) showed 
Fig. 2. Cmpamd acticrn wtential thresholid shifts induced 2 h titter 
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Fig. 3. (A) Dose/threshold shifts curves at 4, 8, 16, and 32 kHz following a 300 mg/kg dose of sodium salicylate. (B) Dose/R decrease curve. 
Same conditions as in A. 
a greater susceptability to sodium salicylate than the 
lower frequencies. After 1 h, only the highest dose (300 
mg/kg) produced a significant threshold shift (data not 
shown). Two h after the injection (Fig. 2), the shift 
reached a level of 16 + 5 dB at 8 kHz and 24 + 9 dB at 
32 kHz for a 300 mg/kg dose. 
Table I shows the averaged changes in CM 2 h post 
injection. No clear changes are seen, although a trend 
toward a decrease in CM (i.e., increased sound level 
for 1 ,uV response) and increased variability are ob- 
served in the group that received 300 mg/kg of sodium 
salicylate compared to the control group. 
The input/output functions for CAP taken for a 16 
kHz tone following 300 mg/kg of sodium salicylate 
showed a low intensity stimulation shift. The CAP 
latency was found consistently increased following 300 
mg/kg. The increase in latency was often greater for 





The dose response relationship for the threshold 
shifts measured 2 h following sodium salicylate at 8, 16, 
and 32 kHz are shown on Fig. 3A. The 300 mg/kg 
dose induced threshold shifts larger than those induced 
by 200 mg/kg for all the frequencies tested. In con- 
trast, the dose-response curve for the R response (Fig. 
3B) appears to saturate for concentrations greater than 
200 mg/kg. 
Effect of sodium salicylate by topical administration 
Topically applied sodium salicylate in the concentra- 
tion of 100 mM did not induce a significant change in 
CAP or CBF. However, doses of 200 mM and 300 mM 
induced a decrease in CBF while the BP was unaf- 
fected (Fig. 4A and B show changes in the R). The 
decrease in CBF was approximately 10% for both 
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Fig. 5. Compound action potential threshold shifts induced by 200 mM (A) and 300 mM (B) sodium salicylate at 1.5, 30, 60, and 120 min following 
the application. 
induced changes. The CAP loss induced by the topical 
applications of 200 and 300 mM was confined to the 
high frequencies (16 kHz and above) and reached a 
maximum 15 min following the application (Figs. 5A 
and 5B). Recovery in auditory sensitivity was observed, 
starting in the first l/2 h post application for the 200 
mM dose and was completed in 1 h. For the 300 mM 
applications, thresholds remained elevated for 1 h and 
then recovered over the following hour. However, for 
300 mg/kg, the recovery was not complete within the 
TABLE I 
Mean sound level changes (in dB) to produce 1 PV rms of cochlear 
microphonics from pre-drug or pre-saline levels 
Frequency (kHz) 




Group S (300 mg/kg) 1.2 
SD 3 
Group S-H - 1.5 
SD 3.7 
Group H-S -4 
SD 6.3 





300 mM -2 * 
SD 2.2 
0.5 -0.5 -1.75 -1.75 -1.75 
1.3 0.6 1.5 3 2 
1.4 3.6 * 6.2 * 8 7.6 
2.7 2.8 5.6 8.2 6.3 
0.5 1 1.5 * 3.25 3.5 
3.7 2.3 1.3 3 4.2 
1.5 -0.25 3.5 2.75 4.25 
2.64 1.5 5.8 3.2 8.3 
2.3 0.7 1.3 6 5.7 
2.9 1.15 3 4.3 3.8 
0.4 1.6 2.8 0.75 2.75 
3.6 2 4.4 0.5 4.9 
0.25 - 1.5 0.25 1.25 5.5 
3.8 2 1.5 1.5 2.6 
Measurements were taken 2 h post systemic administrations and 15 
min post topical applications. t* indicates statistical significance at a 
P level of 0.05). 
2-hr observation period and a 10 dB loss remained at 
32 kHz. No changes in CM were observed (Table I). 
Effect of hydralazine treatment 
CBF changes for the different treatment groups are 
shown in Fig. 6. Group H: Within 5 min following 
topical application of hydralazine, CBF increased slowly 
to about 100% of the baseline value at 1 h post 
administration. The increased CBF was maintained 
throughout the 2-hr observation period. Group SH: 
The initial decrease induced by sodium salicylate was 
similar to the decrease observed in group S (300 mg/kg 
sodium salicylate alone) but then, following the topical 
application of hydralazine (at the 30 min time point), 
CBF increased as in group H. As a result, 1 h after the 
injection of sodium salicylate, CBF overall was overall 
2eor 
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Fig. 6. R changes induced by sodium salicylate (group S), hydralazine 
(group H), and the combined treatment of hydralazine followed by 
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Fig. 7. Compound action potential threshold shifts 2 h after the 
administration of sodium salicylate. The difference was statistically 
significant as tested by unpaired two-tailed t-test with a P value less 
than 0.05 ( * ) or less than 0.005 (* * ). Same groups as in figure 6. 
increased by about 15% compared to the baseline 
value. Group HS: Pretreatment with hydralazine in- 
duced an increased CBF which is shown here at an 
initial level of 150%. Following the administration of 
sodium salicylate, CBF decreased, stabilizing at about 
30% above baseline value. Fig. 7 shows the threshold 
shifts induced in the different groups at various fre- 
quencies at 2 h. In the control group (shown in Fig. 2), 
the sensitivity was not affected. The same was true for 
group H which did not show significant changes in 
sensitivity. The shift at 8 and 16 kHz in group S was 
larger than the shift in group SH and HS. The differ- 
ence was statistically significant as tested by unpaired 
two-tailed t-test with a P value less than 0.05 (*) or 
less than 0.005 (**). 
Discussion 
Use of the LDF allowed us to make a continuous 
measurement of the CBF during the administration of 
sodium salicylate. The contribution of the different 
cochlear vascular beds to the LDF output, however, is 
not known. Theoretically, the major contribution to the 
output of a LDF probe placed over the bony wall of 
the cochlea is made by the lateral wall vessels, a minor 
contribution coming from the basilar membrane or 
modiolar vessels (Miller and Nuttall, 1990). Compari- 
son of the LDF output with measures of the total CBF 
obtained from the microspheres technique indicated 
that the LDF output underestimates but correlates 
well with the CBF increase induced by hemodiiution as 
measured with microspheres (Nuttall et al., 1988). 
The changes in CAP sensitivity and latency pre- 
sented in this study are quite comparable to the earlier 
literature on the subject. In our data (Table I), CM was 
largely unchanged by systemically or topically applied 
salicylate or hydralazine. There was a trend toward 
decreased CM for the systemically given salicylate 
(without hydralazine), which was statistically significant 
for the two mid-frequencies 8 and 16 kHz. Puel et al. 
(1989, 1990) perfused salicylate into the cochlea and 
found either no effect or decreased CM. Stypulkowski 
(1990), in contrast, showed increased levels of CM for 
systemic (IV) injection of salicylate in the cat. The 
variability among these studies could be due to route of 
administration and species differences. 
The results of the current study clearly demonstrate In our data, the significant reduction in CAP is 
a decrease in CBF following the administration of associated, in part, with changes in CBF, which could 
sodium salicylate. This supports the hypothesis of a imply a metabolic component in the salicylate effect. 
vascular action of salicylate in the cochlea. One possi- 
ble mechanism leading to a decreased CBF involves 
the blocking effect of salicylates on the production of 
PGs in the cochlea. The PGs synthesized in the en- 
dothelium of the lateral cochlear wall are PG12 and 
PGE2. These are vasodilating substances. Escoubet et 
al. (1985) found that the production of PGs was abol- 
ished in the cochlea 30 min following the administra- 
tion of a dose of 350 mg/kg of aspirin. Thus, the 
time-course of the decrease observed in the current 
study is very consistent with the actual blockade of PG 
synthesis by salicylates. Jung et al. (1992) has also 
shown that PGs are reduced while the leukotrienes 
(vasoconstrictive substances) are simultaneously in- 
creased. 
In the current study, topical application of sodium 
salicylate led to a smaller and less consistent effect on 
the CBF than the systemic administrations. This may 
imply that the effect of salicylates on the cochlear 
vessels is dependent on the route followed by the drug. 
Given systemically, the drug most likely reaches the 
cochlea by diffusion from the blood vessels (Jastreboff 
et al., 1988). Ishii et al. (1967) were able to show by 
autoradiography that sodium salicylate is first incorpo- 
rated into the walls of stria vascularis blood vessels 
before reaching the perilymphatic and endolymphatic 
spaces. One can hypothesize that, when given topically, 
sodium salicylate induced a smaller effect because the 
concentration in the area of the blood vessels did not 
reach a sufficiently high level. Jung et al. (1991) ob- 
tained an apparently larger CBF decrease for round 
window applied salicylate (150 Fg vs 48 kg maximum 
dose delivered in 1 ~1 to the round window in the 
current study), but no dose-response data were given to 
assess whether the response was maximal. It is consis- 
tent that our data, obtained after systemic administra- 
tion, show that the decrease in CBF is the earlier 
manifestation of the drug since it is seen in the blood 
vessels that are reached first by the drug. 
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This hypothesis is consistent with the data showing that 
CAP is more susceptible than CM or the endocochlear 
potential (EP) to hypoxia (Brown et al., 1983b1, and 
with the slight decrease in EP induced by salicylates 
(Puel et al., 1990; Stypulkowski, 1990). 
To help clarify the contribution of a vascular compo- 
nent of sodium salicylate toxicity, we conducted the set 
of experiments in which CBF was increased in the 
presence of hydralazine thereby partly or fully negating 
the CBF reduction by salicylate. Hydralazine is effi- 
cient in increasing CBF over long period of time 
(OhlsCn et al., 1990). In the current experiments, hy- 
dralazine at the concentration of 20 mg/ml does not 
alter cochlear sensitivity (however, higher doses have 
been reported to impair the sound-evoked responses of 
the cochlea (OhlsCn et al., 1993). It should be noted 
also that the increase in CBF induced by hydralazine 
does not ‘improve’ or cause hypersensitivity in the 
normal ear. Sodium salicylate-induced threshold shifts 
were reduced by the hydralazine treatment. When suc- 
cessively applied in the same animal, the effect of 
hydralazine as well as of sodium salicylate was of a 
similar magnitude and time course regardless of the 
protocol used (salicylate before hydralazine or hydrala- 
zine before salicylate). We conclude from this that 
there is no pharmacological interaction of the two 
drugs on their site of action on blood flow and that the 
higher CBF in hydralazine-treated animals could ac- 
count for the reduction in sodium salicylate-induced 
loss in sensitivity. This result is of interest from a 
clinical viewpoint. It demonstrates in an animal model 
of vascular pathology, the efficacy of a vasodilating 
treatment. 
Based on the dose-response curves for threshold 
shifts and change in CBF/BP (Figs. 1 and 21, we can 
conclude that a 10% decrease in R, induced by a 100 
mg/kg dose, has no effect on the cochlear function, 
These figures also show that the dose relationship is 
different for changes in sensitivity and in CBF: CBF 
decrease saturates at 200 mg/kg while CAP thresholds 
continue to increase above 200 mg/kg. This suggests 
that different mechanisms are involved, and one should 
not expect a close correlation between CBF changes 
and sensitivity changes. 
However, taken together, our results indicate that 
the salicylate-induced decrease in CBF could be partly 
responsible for or potentiate the loss in sensitivity. 
Further studies, using specifically vasoactive drugs, 
should focus on assessing the causal relationship be- 
tween a decreased CBF and impairment of cochlear 
function. 
In the present experiments, the primary effect of 
hydralazine in reducing the salicylate-induced thresh- 
old shift is restricted to the mid-frequencies. The rea- 
son for this effect is not clear. High frequencies are 
known to be susceptible to surgical trauma and other 
factors. Thus, even if in the control group, the high 
frequencies are well preserved it is possible that an 
additive factor potentiates the salicylate toxicity at high 
frequencies. 
Summary 
This study demonstrates sodium salicylate-induced 
decreases in CBF that can occur without sensitivity 
changes (for low salicylate doses). Increasing CBF by 
an independent mechanism provides some protection 
to the cochlea from the adverse effect of sodium salicy- 
late. We conclude then that the low CBF induced by 
salicylate is part of the toxic mechanism leading to 
salicylate-induced hearing loss. These results would 
need to be taken into account in studies exploring the 
interactive mechanism of salicylates with other 
cochleotoxic agents, particularly with noise which has 
also been shown to influence CBF (Axelsson et al., 
1987; Quirk et al., 1991; Thorne and Nuttall, 1987; 
Ryan, 1988). 
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